循环血清中miRNA作为多发性骨髓瘤诊断标志的研究

发布时间：2018-04-23 08:51

本文选题：循环血清中miRNA + 多发性骨髓瘤　；参考：《中国实验血液学杂志》2017年02期

【摘要】：目的:探讨循环血清中miRNA的变化对骨髓瘤的诊断价值。方法:收集2013年7月至2014年6月就诊于厦门大学中山医院的40例骨髓瘤患者血液样品,应用实时荧光定量PCR方法检测处于不同临床阶段骨髓瘤患者及20名健康志愿者循环血清中的miRNA(包括miR-29a,miR-155,miR-16和miR-92a)表达水平,分析miRNA表达的变化对骨髓瘤的诊断价值。结果:与健康捐献者相比,初诊的骨髓瘤患者血清miR-29a水平显著升高(P0.01),而miR-155水平显著降低(P0.001)。检测miR-29a/miR-155比值可以有效地区分健康者和骨髓瘤患者,诊断灵敏性为80.8%,特异性83.3%。骨髓瘤患者血清miR-29a水平与骨髓浆细胞数和患者血清M蛋白水平始终保持一致。结论:血清中miR-29a,miR-155和miR-16值的变化可以作为多发性骨髓瘤患者的分子生物学诊断标志,其中miR-29a/miR-155值对骨髓瘤诊断价值最高。
[Abstract]:Objective: to investigate the diagnostic value of miRNA in circulating serum for myeloma. Methods: blood samples were collected from 40 patients with myeloma from July 2013 to June 2014 in Zhongshan Hospital of Xiamen University. The expression levels of miRNAs (including miR-29aOmiR-155miR-16 and miR-92a) in circulating serum of myeloma patients and 20 healthy volunteers at different clinical stages were detected by real-time fluorescence quantitative PCR. The diagnostic value of the changes of miRNA expression in myeloma was analyzed. Results: compared with the healthy donors, the serum miR-29a level of the newly diagnosed myeloma patients was significantly higher than that of the healthy donors, while the miR-155 level was significantly lower than that of the healthy donors. Detection of miR-29a/miR-155 ratio can effectively distinguish healthy and myeloma patients, the diagnostic sensitivity is 80.8 and the specificity is 83.3. The serum miR-29a level of myeloma patients was consistent with the number of bone marrow plasma cells and serum M protein levels. Conclusion: the changes of miR-29a miR-155 and miR-16 values in serum can be used as molecular diagnostic markers for multiple myeloma patients, and miR-29a/miR-155 value is the most valuable in the diagnosis of multiple myeloma.
【作者单位】：厦门大学附属中山医院血液科;
【基金】：国家自然科学基金面上课题(81172246)
【分类号】：R733.3

【相似文献】